Short answer
Jade Biosciences, Inc. (JBIO) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$25M
- −55.0% YoY · +62.9% QoQ
- EPS (diluted)
- $0.37
- +164.9% YoY · +111.0% QoQ
Source: XBRL data from the Jade Biosciences, Inc. (JBIO) Q3 2025 10-Q on SEC EDGAR. USD.
Jade Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No identifiable new or changed risk factors; provided excerpt contains MD&A and liquidity disclosures, not the 10-Q Risk Factors section
- Regulatory risk: product candidates may never obtain approval, delaying any product revenue
- Operational risk: JADE101 Phase 1 development and JADE201 preparation require substantial continuing expenditures
- Financial risk: $61.0 million operating cash use during the nine months ended September 30, 2025
- Liquidity risk: $198.9 million cash and investments expected to fund operations at least twelve months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Jade Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.